I-O Treatment vs. TKI Treatment TKI is Still Standard of Care for Good-Risk Patients

I-O Treatment vs. TKI Treatment TKI is Still Standard of Care for Good-Risk Patients
Eric Jonasch, MD, UT MD Anderson Cancer Center explains I-O Treatment vs. TKI Treatment | TKI is Still Standard of Care for Good-Risk Patients at Annual Meeting 2018
157 Views
5 years Ago
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Liver

Ghassan Abou-Alfa, MD - HIMALAYA Phase III trial - Tremelimumab accepted under Priority Review in the US for patients with unresectable liver cancer in combination with Imfinzi.m4v
Ghassan Abou-Alfa, MD - HIMALAYA Phase III trial - Tremelimumab accepted under Priority Review in the US for patients...
67 Views
Allen Wilbanks
NRG / RTOG 1112 Phase 3 Trial: ASTRO [2022]
NRG / RTOG 1112 Phase 3 Trial: ASTRO [2022]
82 Views
ASTRO
NRG / RTOG 1112 Phase 3 Trial: ASTRO [2022]
NRG / RTOG 1112 Phase 3 Trial: ASTRO [2022]
280 Views
ASTRO
Rencofilstat in HCC: What You Need To Know
Rencofilstat in HCC: What You Need To Know
391 Views
Cancer News
Podcast Mindie H. Nguyen, MD @Stanford @Stanford_GI #HelioLiver #LiverCancer ENCORE Data: HelioLiver For Liver Cancer
Podcast Mindie H. Nguyen, MD @Stanford @Stanford_GI #HelioLiver #LiverCancer ENCORE Data: HelioLiver For Liver Cancer
71 Views
Cancer News
Mindie H. Nguyen, MD @Stanford @Stanford_GI #HelioLiver #LiverCancer ENCORE Data: HelioLiver For Liver Cancer
Mindie H. Nguyen, MD @Stanford @Stanford_GI #HelioLiver #LiverCancer ENCORE Data: HelioLiver For Liver Cancer
248 Views
Cancer News
Podcast Professor Amit Singal @docamitgs @UTSWNews @utswcancer #HCC #LiverCancer Primary and Secondary Prevention: HCC
Podcast Professor Amit Singal @docamitgs @UTSWNews @utswcancer #HCC #LiverCancer Primary and Secondary Prevention: HCC
68 Views
ESMO
Professor Amit Singal @docamitgs @UTSWNews @utswcancer #HCC #LiverCancer Primary and Secondary Prevention: HCC
Professor Amit Singal @docamitgs @UTSWNews @utswcancer #HCC #LiverCancer Primary and Secondary Prevention: HCC
39 Views
ESMO
Podcast Daniel Rotroff, PhD @danielrotroff @FAucejo @ClevelandClinic #HCC #Biomarkers Salivary miRNAs As Non-invasive Biomarkers
Podcast Daniel Rotroff, PhD @danielrotroff @FAucejo @ClevelandClinic #HCC #Biomarkers Salivary miRNAs As Non-invasive...
23 Views
Cancer News
Daniel Rotroff, PhD @danielrotroff @FAucejo @ClevelandClinic #HCC #Biomarkers Salivary miRNAs As Non-invasive Biomarkers
Daniel Rotroff, PhD @danielrotroff @FAucejo @ClevelandClinic #HCC #Biomarkers Salivary miRNAs As Non-invasive Biomarkers
31 Views
Cancer News
Podcast- Jerome Goldschmidt, MD- Understanding Hematological Adverse Event Management through Health Care Resource Utilization, Costs, and Treatment Patterns of Patients with Extensive-St...
Podcast- Jerome Goldschmidt, MD- Understanding Hematological Adverse Event Management through Health Care Resource Ut...
16 Views
ASH
Jerome Goldschmidt, MD- Understanding Hematological Adverse Event Management through Health Care Resource Utilization, Costs, and Treatment Patterns of Patients with Extensive-Stage Small...
Jerome Goldschmidt, MD- Understanding Hematological Adverse Event Management through Health Care Resource Utilization...
15 Views
ASH